Back to Journals » Research Reports in Clinical Cardiology » Volume 5

Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome

Authors Krohn-Grimberghe M, Bode C, von zur Muhlen C

Received 4 January 2014

Accepted for publication 3 March 2014

Published 13 May 2014 Volume 2014:5 Pages 103—109

DOI https://doi.org/10.2147/RRCC.S38727

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Marvin Krohn-Grimberghe, Christoph Bode, Constantin von zur Muhlen

Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany

Abstract: Angioplasty and stent implantation have greatly improved the outcome of patients with acute coronary syndrome. However, stents come with the risk of stent thrombosis, which is associated with a high rate of revascularization, myocardial infarction, and death. The inhibition of factor Xa due to rivaroxaban leads to an interruption of the intrinsic as well as the extrinsic coagulation pathway, which reduces thrombus formation as a potential mechanism to diminish the rate of stent thrombosis. In this review, we evaluate the role of rivaroxaban in the prevention of stent thrombosis and its general role in patients with acute coronary syndrome.

Keywords: Rivaroxaban, stent thrombosis, acute coronary syndrome, secondary prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]